Clinical trials: Cardiac Ischemia
Coronary Artery Disease
Study Effect of VIA-2291 on Vascular Inflammation
This is a dose ranging study to compare the effect of VIA-2291 vs. Placebo on various inflammatory biomarkers in patients with recent acute coronary events
- Trial name
- NCT00358826
- Testing
- VIA-2291
- Where
- 12 sites in United States, Canada
- Volunteers
- 191 people
- Sponsor
- Tallikut Pharmaceuticals, Inc.
Coronary Artery Disease
Prospective, Single-arm, Multi Centre Observations Ultimaster Des Registry
The e-Ultimaster will further validate the safety and efficacy of Ultimaster DES system in unselected patients representing everyday clinical practice.
- Trial name
- e-Ultimaster (NCT02188355)
- Where
- 462 sites in Argentina, Armenia and 48 more
- Volunteers
- 37,000 people
- Sponsor
- Terumo Europe N.V.
Cardiac Surgical Procedures, Coronary Artery Disease
Clinical Outcomes in Patients Treated With SternaLock Blu
The primary objective of this study is to evaluate the rate of deep sternal wound infection at 30 days post-operative following a full median sternotomy in patients treated with SternaLock Blu for rigid sternal fixation.
- Conditions
- Cardiac Surgical Procedures, Coronary Artery Disease, Heart Valve Diseases
- Trial name
- SECURE (NCT03709693)
- Testing
- SternaLock Blu
- Where
- 4 sites in United States
- Volunteers
- 156 people, healthy volunteers welcome
- Sponsor
- Zimmer Biomet
Coronary Artery Bypass Graft Surgery, Myocardial Ischemia
A Safety and Efficacy Study to Confirm the Cardioprotective Effects of MC-1 in Patients Undergoing High-Risk CABG
The purpose of this study is to determine the effect of MC-1 on the combined incidence of cardiovascular death and nonfatal myocardial infarction (MI) up to and including 30 days following coronary artery bypass graft (CABG)…
- Conditions
- Coronary Artery Bypass Graft Surgery, Myocardial Ischemia, Reperfusion Injury
- Trial name
- NCT00402506
- Testing
- (MC-1) Pyridoxal 5'-phosphate
- Where
- 2 sites in United States, Canada
- Volunteers
- 3,000 people
- Sponsor
- Medicure
Acute Coronary Syndrome (ACS)
Evaluation on the Safety of Ticagrelor Among Chinese ACS Patients
The primary objective is to describe the safety and tolerability of ticagrelor, by assessment of adverse events (characteristics, reporting rate, severity, relationship and risk factors), especially the bleeding events as defined…
- Trial name
- YingLong (NCT02430493)
- Where
- 15 sites in China
- Volunteers
- 1,066 people
- Sponsor
- AstraZeneca
Myocardial Infarction, Unstable Angina Pectoris, Sudden Cardiac Death, Stroke, Peripheral Artery Disease
Protective Effect of EPA on Cardiovascular Events
The purpose of this study was to test the hypothesis that the long-term use of highly (>98%) purified EPA, in addition to HMG-CoA reductase inhibitor (statin), would be more effective than statin alone in preventing…
- Trial name
- NCT00231738
- Testing
- Eicosapentaenoic acid ethyl ester(EPADEL Capsule 300 TM)
- Where
- Japan
- Volunteers
- 18,000 people
- Sponsor
- Kobe University
Hypercholesterolemia, Atherosclerosis
Switching to Rosuvastatin Versus Adding Ezetimibe to Atorvastatin Versus Doubling the Dose of Atorvastatin in Patients With Hypercholesterolemia and Risk Factors (P03708)
This study assesses whether adding ezetimibe 10 mg/d to ongoing treatment with atorvastatin 10 mg/d is more effective than switching the subject to treatment with rosuvastatin 10 mg/d or doubling the dose of atorvastatin to 20…
- Conditions
- Hypercholesterolemia, Atherosclerosis, Coronary Artery Disease
- Trial name
- NCT00651378
- Testing
- Rosuvastatin, Ezetimibe + Atorvastatin, Double Atorvastatin
- Volunteers
- 87 people
- Sponsor
- Organon and Co
Hypercholesterolemia, Coronary Disease
Co-administration Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-803)
The purpose of this study is to investigate additional cholesterol lowering effects in patients with coronary heart disease by giving an investigational drug with a patient's current approved cholesterol lowering medication.
- Trial name
- NCT00092625
- Testing
- MK0653, ezetimibe
- Volunteers
- 442 people
- Sponsor
- Organon and Co
Atrial Fibrillation
Burden of Ischemic Stroke and Intake of Oral Anticoagulants in Patients With Atrial Fibrillation in the UK Primary Care
This study will characterize patients with ischemic stroke, a condition which occurs when a vessel supplying blood to the brain is obstructed, and a subpopulation of patients with irregular and often rapid heart rate (atrial…
- Trial name
- BEST-AF (NCT04099238)
- Testing
- Oral anticoagulant
- Where
- United Kingdom
- Volunteers
- 3,739 people
- Sponsor
- Bayer
Stable Angina
COBRA SHIELD OCT Study
Phase one of this study is a prospective, randomized (2:1), pilot study that will evaluate COBRA PzF vascular healing patterns and thrombus formation with Optical Coherence Tomography (OCT) at 3 months after stent implantation in…
- Trial name
- NCT02224235
- Testing
- Aspirin, Resolute Integrity DES, COBRA PzF
- Where
- 2 sites in Finland
- Volunteers
- 8 people
- Sponsor
- CeloNova BioSciences, Inc.
Coronary Artery Disease, Myocardial Ischemia
AngioSculpt® Coronary Bifurcation Study
The purpose of this study is to evaluate a new angioplasty catheter, AngioSculpt® for the treatment of bifurcation lesions (blockages occurring at branch points) in coronary arteries.
- Trial name
- AGILITY (NCT00686647)
- Testing
- AngioSculpt® Scoring Balloon Catheter, AngioSculpt Scoring Balloon Catheter
- Where
- United States
- Volunteers
- 93 people
- Sponsor
- AngioScore, Inc.
Heart Failure
Prospective Study of the BioVentrix PliCath HF™ System for the Treatment of Ischemic Cardiomyopathy
The purpose of the study is to determine the safety, and feasibility of a device, which enables LV volume and radius reduction through scar exclusion in patients whose systolic HF is due to ischemic cardiomyopathy.
- Trial name
- CONFIGURE-HF (NCT01568138)
- Testing
- PliCath HF System
- Where
- 4 sites in Latvia, Lithuania and 2 more
- Volunteers
- 26 people
- Sponsor
- BioVentrix
Coronary Artery Disease, Cerebro Vascular Disease
Study the Result of Ayurvedic SUVED & Reimmugen (Colostrum) Treatment on Vascular Disease, CAD, CVA, DVT.
To evaluate the benefits of Ayurvedic SUVED \& REIMMUGEN Colostrum for reduction/reversal of symptoms and study clinical progress in Vascular disease; CAD, CAV, Stroke, DVT patients.
- Conditions
- Coronary Artery Disease, Cerebro Vascular Disease, Ischemic Heart Disease, Deep Vein Thrombosis
- Trial name
- SHARP (NCT02920125)
- Testing
- SUVED, REIMMUGEN
- Where
- India
- Volunteers
- 96 people
- Sponsor
- Sujata Vaidya
Coronary Artery Disease
A Study of the Cypher Sirolimus-Eluting Stent to Treat Bifurcation Lesions.
The objective of this study is to assess the feasibility and safety of the sirolimus-coated Bx VELOCITY Balloon-Expandable Stent in treating patients with true bifurcation lesions.
- Trial name
- BIFURCATION (NCT00234455)
- Testing
- drug eluting-stent, drug-eluting stent
- Where
- Italy
- Volunteers
- 86 people
- Sponsor
- Cordis US Corp.
Heart Transplantation
Non-ischemic Preservation of the Donor Heart in Heart Transplantation
The study intends to compare standard ischemic cold static storage (ICSS) of retrieved hearts intended to be transplanted, to non-ischemic heart preservation (NIHP) in a randomized clinical multicentre trial.
- Trial name
- NCT03991923
- Testing
- XVIVO heart preservation devices, Standard ICSS
- Where
- 15 sites in Austria, Belgium and 6 more
- Volunteers
- 230 people
- Sponsor
- XVIVO Perfusion
Myocardial Ischemia
Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary Syndromes
MERLIN-TIMI 36 is a multi-national, double-blind, randomized, placebo-controlled, parallel-group clinical trial designed to evaluate the efficacy and safety of ranolazine during acute and long-term treatment in approximately…
- Trial name
- NCT00099788
- Testing
- Ranolazine
- Where
- United States
- Volunteers
- 6,560 people
- Sponsor
- Gilead Sciences
Coronary Artery Disease
Evaluation of the GTX™ 5126 DES Coronary Stent System in the Treatment of Patients With a Lesion in the Coronary Artery
The GTX™ Drug Eluting Coronary Stent System is intended for the treatment of patients with a lesion in the coronary artery.
- Trial name
- NCT00777842
- Testing
- GTX™ Drug Eluting Coronary Stent System
- Where
- Germany
- Volunteers
- 19 people
- Sponsor
- Cook Group Incorporated
Coronary Artery Disease (CAD), Coronary Atherosclerosis
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
The study will assess the change in coronary atherosclerotic disease as determined by intravascular ultrasound (IVUS) for aliskiren compared to placebo when given in addition to standard therapy in patients with coronary artery…
- Trial name
- AQUARIUS (NCT00853827)
- Testing
- Aliskiren
- Where
- 129 sites in United States, Argentina and 9 more
- Volunteers
- 613 people
- Sponsor
- Novartis Pharmaceuticals
Coronary Artery Disease
DynamX Bioadaptor Hong Kong Registry
Prospective, non-randomized, multicenter registry
- Trial name
- NCT04483791
- Testing
- DynamX Novolimus Eluting Coronary Bioadaptor System
- Where
- 4 sites in China
- Volunteers
- 50 people
- Sponsor
- Elixir Medical Corporation
Acute Coronary Syndrome
Enoxaparin Versus Unfractionated Heparin in Subjects Who Present to the Emergency Department With Acute Coronary Syndrome (RESCUE)
The purpose of this study is to determine the efficacy and safety of enoxaparin compared to unfractionated heparin (UFH) for patients diagnosed with Acute Coronary Syndrome (ACS) in the emergency department (ED).
- Trial name
- NCT00077818
- Testing
- Enoxaparin sodium
- Sponsor
- Sanofi
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.